IL-27R alpha/WSX-1/TCCR Antibody (263503) [Unconjugated]

Mouse splenocytes were stained with Rat Anti-Mouse IL‑27 R alpha /WSX‑1/TCCR Monoclonal Antibody (Catalog # MAB21091, filled histogram) or isotype control antibody (Catalog # MAB0061, open histogram) followed by Allophycocyanin-conjugated Anti-Rat IgG Secondary Antibody (Catalog # F0113). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Mu
• Applications: WB, Flow, CyTOF-ready
• Clone: 263503
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-27R alpha/WSX-1/TCCR Antibody (263503) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse IL-27 R alpha /WSX‑1/TCCR
  Gly29-Lys510
  Accession # O70394
• Specificity: Detects mouse IL-27 R alpha /WSX‑1/TCCR in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse gp130 or recombinant human IL-27 R alpha is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Gene: IL27RA
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-27R alpha/WSX-1/TCCR Antibody (263503) [Unconjugated]

• class I cytokine receptor
• CRL1IL-27R
• Cytokine receptor-like 1
• IL-27 R alpha
• IL27R alpha
• IL27R
• IL27RA
• IL-27Ra
• IL-27R-alpha
• interleukin 27 receptor, alpha
• interleukin-27 receptor subunit alpha
• TCCR
• TCCRIL-27 receptor subunit alpha
• T-cell cytokine receptor type 1
• Type I T-cell cytokine receptor
• WSX-1
• WSX1IL-27R subunit alpha
• zcytor1

Background

IL‑27 R alpha (also known as WSX‑1 and TCCR) is a 85‑95 kDa member of the type I, group 2 cytokine receptor family (1‑6). Mature IL‑27 R alpha is a type I transmembrane glycoprotein that contains a 486 amino acid (aa) extracellular region, a 21 aa transmembrane segment and a 92 aa cytoplasmic domain. Consistent with type I cytokine receptors, the extracellular region contains four positionally conserved cysteine residues, a WSxWS motif (for receptor folding and ligand binding), and three fibronectin type III repeats. The intracellular domain contains a “box‑1” motif that may be involved with Janus kinases (3). In mouse, a soluble 33 kDa splice form that shows a 20 aa substitution for aa 251‑623 has been identified (7). The mouse IL‑27 R alpha extracellular region shares 63% amino acid identity with the human IL‑27 R alpha extracellular domain (2, 3). IL‑27 R alpha is expressed in mast cells, endothelial cells, NK cells, macrophages, monocytes, B cells, dendritic cells, and naïve T cells (1, 2, 4, 8). Typical of other class I cytokine receptor chains, the ligand binding IL‑27 R alpha molecule is known to heterodimerize with a signal‑transducing subunit (gp130) to form a functional IL‑27 receptor (9, 10). In addition, IL‑27 R alpha is reported to complex with CNTFR alpha and gp130 form a humanin receptor on neurons (7, 11), and to complex with gp130 and IL‑6 R to form a receptor for a p28:CLF heterodimeric cytokine on lymphocytes (12). Studies using IL‑27 R alpha /WSX‑1^-/- mice reveal that IL‑27 has the ability to suppress T cell activity during infection, and to mediate an inhibition of both type 1 and type 2 T cell immunity (4, 13, 14). In particular, IL‑27 is known to act on naïve T cells, blocking their differentiation into a Th17 phenotype. Notably, cells committed to a Th17 phenotype, although they express a functional IL‑27 receptor, are unresponsive to the effects of IL‑27 (15). Activated T cells that are CD4+ and CD8+, and which express the IL‑27 receptor, can be induced by IL‑27 to form a double‑positive CD25⁺ FoxP3^- IFN‑ gamma plus IL‑10 secreting phenotype that both promotes and suppresses the inflammatory response (16).

1. Villarino, A.V. et al. (2004) J. Immunol. 173:715.
2. Chen, Q. et al. (2000) Nature 407:916.
3. Sprecher, C.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:82.
4. Artis, D. et al. (2004) J. Immunol. 173:5626.
5. Yoshida, H. and Y. Miyazaki (2008) Int. J. Biochem. Cell Biol. 40:2379.
6. Yoshida, H. and M. Yoshiyuki (2008) Immunol. Rev. 226:234.
7. Hashimoto, Y. et al. (2009) Biochem. Biophys. Res. Commun. 389:95
8. Holscher, C. et al. (2005) J. Immunol. 174:3534.
9. Pflanz, S. et al. (2004) J. Immunol. 172:2225.
10. Scheller, J. et al. (2005) Biochem. Biophys. Res. Commun. 326:724.
11. Hashimoto, Y. et al. (2009) Mol. Biol. Cell 20:2864.
12. Crabe, S. et al. (2009) J. Immunol. 183:7692.
13. Villarino, A. et al. (2003) J. Immunol. 170:645.
14. Hamano., S. et al. (2003) Immunity 19:657.
15. El-behi, M. et al. (2009) J. Immunol. 183:4957.
16. Fitzgerald, D.C. et al. (2007) Nat. Immunol. 8:1372.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-27R alpha/WSX-1/TCCR Antibody (MAB21091)(4)

Publications using MAB21091

• Min, K;Kim, D;Jo, M;Choi, M;Lee, D;Park, J;Park, Y;Chung, Y;Kim, Y;Park, Y;Kim, H;Choi, W; IL-27-induced PD-L1highSca-1+ innate lymphoid cells suppress contact hypersensitivity in an IL-10-dependent manner Experimental & Molecular Medicine 2024-03-01 [PMID: 38424193] (Flow Cytometry, Mouse)
• Katarzyna Składanowska, Yehudi Bloch, Jamie Strand, Kerry F. White, Jing Hua, Daniel Aldridge et al. Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27 Cell Reports 10/18/2022 [PMID: 36261006]
• Mascanfroni , Ivan D, Yeste , Ada, Vieira , Silvio M, Burns , Evan J, Patel , Bonny, Sloma , Ido, Wu , Yan, Mayo , Lior, Ben-Hamo , Rotem, Efroni , Sol, Kuchroo , Vijay K, Robson , Simon C, Quintana , Francisc IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol, 2013-09-01;14(10):1054-63. 2013-09-01 [PMID: 23995234] (Western Blot, Mouse)
• Pradhan A, Lambert QT, Reuther GW Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc. Natl. Acad. Sci. U.S.A., 2007-11-14;104(47):18502-7. 2007-11-14 [PMID: 18003935] (Flow Cytometry, Mouse)

Bioinformatics

• Gene Symbol: IL27RA
• Uniprot:
  • O70394()